Angiotropins of leukocytes and inflamed tissue, process for their biotechnical preparation, and pharmaceutical compositions thereof

Claim 2

Angiotropins of leukocytes and inflamed tissue, characterized by the following properties: (a) biological activities in vivo and in vitro: specific chemotropic action on blood vessels in vivo; induction of directional growth (chemotropism) of blood vessels along its concentration gradient; during vessel sprouting, tips of growing vessel capillaries have increased capillary permeability (FIG. 1); induction of neovascularization of tissues by directional in-growth of blood vessels (FIG. 1 and 2); (b) physico-chemical properties: electrophoretic migration in acrylamide matrices at a pH of 7.40 is anodic; soluble in aqueous media including in 20% ethanol at a pH value of at least 4.0 to 10; constant temperature coefficient of solubility in ammonium sulfate solutions between -10° C. and +50° C.; they absorb reversibly in structure and biological activity on anion and cation exchangers, calcium phosphate gel and hydroxyapatite and can be subjected in native form to volume partition chromatography.

Claim 3

Angiotropins according to claim 1, obtainable from leukocytes, by culturing leukocytes and isolation from the supernatant culture solution or from inflamed tissue.

Claim 4

Angiotropin (Monocyto-angiotropin) according to claims 1 or 2 characterized in that it is obtainable from mononuclear leukocytes and possesses the following additional properties: effective threshold dose in vivo:<2,5 fmol molecular weight of the native protein (primary structure); approximately 4,500 dalton; no protein quaternary structure in the form of physically bound peptide subunits: each of the native proteins consists of only one peptide unit soluble in an ammonium sulfate solution at 90% saturation (3.6 mol/l); it contains, amongst others, the amino acids tyrosine, phenylalanine, alanine, glycine, valine, cysteine and aspartic acid; absorption spectrum (UV, visible and near IR-range) as given in FIG. 3; extinction coefficients according to the following Table I: TABLE I ______________________________________ wave length, nm E.sub.1 mg/ml, 1 cm (H.sbsb.2.sub.O, 20° C.) ± ______________________________________ 6% 250 (min) 0.18 260 0.28 277 (max) 0.49 280 0.48 290 0.30 400-1000 0 E.sub.280 /E.sub.260 1.71 ______________________________________

Claim 5

Angiotropin (granulocyto-angiotropin) according to claims 1 or 2, characterized in that it is obtainable from granulocytes and possesses the following additional properties: effective threshold dose in vivo:<50 fmol molecular weight of the native protein (primary structure): approximately 35,000 dalton; insoluble in an ammonium sulfate solution at 35% saturation (1.4 mol/l); it contains, amongst others the amino acids tyrosine, phenylalanine, alanine, glycine, valine, cysteine, aspartic acid, proline and arginine; absorption spectrum (UV, visible and near IR-range) according to FIG. 4; extinction coefficient according to the following Table II: TABLE II ______________________________________ wave length, nm E.sub.1 mg/ml, 1 cm (H.sbsb.2.sub.O, 20° C.) + ______________________________________ 6% 250 (min) 0.21 260 0.30 277 (max) 0.59 280 0.58 290 0.35 400-1000 0 E.sub.280 /E.sub.260 1.93 ______________________________________

Claim 6

A pharmaceutical composition for specifically influencing the angiogenesis and the vascular condition of a tissue of the body of mammalians, comprising an effective amount of at least one angiotropin according to any one of claims 1 to 4 together with a suitable carrier therefor.

Claim 7

A pharmaceutical composition for specifically influencing the angiogenesis and the vascular condition of a tissue of the body of mammalians, comprising an effective amount of at least one antiangiotropin-immunoglobulin and a suitable carrier therefor.

Claim 8

A pharmaceutical composition for specifically influencing the angiogenesis and the vascular condition of a tissue of the body of mammalians, comprising an effective amount of at least one antiangiotropin-immunoglobulin and a suitable carrier therefor.

Claim 12

A process for producing and isolating angiotropins, which comprises: a. culturing a population of leukocytes in a suitable culture medium; b. separating the leukocytes from the culture medium after termination of culturing; c. adding a sufficient amount of a suitable salt to the culture solution to precipitate a first protein fraction from said culture medium; d. concentrating said salted culture medium to obtain a second protein fraction which is soluble therein; and e. separately purifying each of said first and second protein fractions by preparative and analytical molecular sieve filtration, anion and cation exchange chromatography, chromatography and hydroxyapatite, zone precipitation chromatography, and recycling or cascade molecular sieve filtration to obtain angiotropins.

Claim 13

A process for producing and isolating angiotropins, which comprises: a. culturing a population of leukocytes in a suitable culture medium; b. separating the leukocytes from the culture medium after termination of culturing; c. adding a sufficient amount of a suitable salt to the culture solution to precipitate a first protein fraction from said culture medium; d. concentrating said salted culture medium to obtain a second protein fraction which is soluble therein; and e. separately purifying each of said first and second protein fractions by preparative and analytical molecular sieve filtration, anion and cation exchange chromatography, chromatography and hydroxyapatite, zone precipitation chromatography, and recycling or cascade molecular sieve filtration to obtain angiotropins.

Claim 14

The process according to claim 9, wherein a mixed leukocyte population is cultured.

Claim 15

The process according to claim 9, wherein a specific leukocyte type is cultured.

Claim 16

The process according to claim 9, wherein the leukocytes are cultured in a fully synthetic cell culture medium containing serum albumin as the only protein.

Claim 17

The process according to claim 9, wherein the mitosis of the leukocytes is induced during the culture.

Claim 18

The process according to claim 13, wherein a polyvalent mitogen and endotoxin-mitogen is added.

Claim 19

The process of claim 13, wherein an immune reaction is promoted on the cell surface so as to induce the mitosis of the leukocytes.

Claim 20

The process according to claim 14, wherein the mitosis of the leukocytes is induced by the addition of a lectin.

Claim 21

The process according to claim 16, wherein a lectin from Canavalia ensiformis (Concanavalin A=CON) is used.

Claim 22

The process according to claim 12, wherein the leukocytes are cultured in a cell culture medium having the composition given in Table III.

Claim 23

The process according to claim 18, wherein the leukocytes are cultured for approximately 40 hours, at a temperature of about 37° C., a concentration of about 10 7 to 10 8 cells/ml of culture medium and a CO 2 -partial pressure of about 1% while sufficient oxygen is supplied to the culture.

Claim 24

The process according to claim 19, wherein ammonium sulfate is used to precipitate said proteins.

Claim 25

The process according to claim 20, wherein the ammonium sulfate concentration of the culture solution is increased stepwise and the proteins precipitated after each ammonium sulfate addition are separated from the culture solution thereby obtaining at least two crude protein fractions having differing solubilities at different ammonium sulfate concentrations.

Claim 26

The process according to claim 16, wherein the ammonium sulfate concentration of the culture solution is adjusted stepwise to 35%, 45% and 90% saturation.

Claim 27

The process according to claim 19, wherein the supernatant liquid is concentrated by ultrafiltration or dialysis after separation of the protein precipitate.

Claim 28

The process according to claim 9, wherein at least two of said purification steps are performed in sequence.

Claim 29

The process according to claim 24, wherein at least three of said purification steps are performed in sequence.

Claim 30

The process according to claim 9, wherein said anion and cation exchange chromatography steps are performed as batch adsorption processes.

Claim 31

A process for producing and isolating monocyto-angiotropin which comprises: a. culturing a leukocyte population in a culture medium; b. inducing the mitosis of the cells using CON during culturing; c. separating said cells from said medium; d. adding ammonium sulfate up to 90% saturation to said culture medium to precipitate proteins; e. separating the precipitated proteins from the ammonium sulfate containing supernatant; f. concentrating and purifying the supernatant by preparative molecular sieve filtration, anion exchange chromatography, cation exchange chromatography, hydroxyapatite chromatography, zone precipitation chromotography and recycling molecular sieve filtration; and g. isolating the monocyto-angiotropin in highly purified form from the eluate of recycling molecular sieve filtration, after separating the accompanying foreign proteins.

Claim 32

A process for producing and isolating monocyto-angiotropin which comprises: a. culturing a leukocyte population in a culture medium; b. inducing the mitosis of the cells using CON during culturing; c. separating said cells from said medium; d. adding ammonium sulfate up to 90% saturation to said culture medium to precipitate proteins; e. separating the precipitated proteins from the ammonium sulfate containing supernatant; f. concentrating and purifying the supernatant by preparative molecular sieve filtration, anion exchange chromatography, cation exchange chromatography, hydroxyapatite chromatography, zone precipitation chromotography and recycling molecular sieve filtration; and g. isolating the monocyto-angiotropin in highly purified form from the eluate of recycling molecular sieve filtration, after separating the accompanying foreign proteins.

Claim 33

The process of claim 27, wherein said leukocyte population consists of monocytes.

Claim 34

The process of claim 27, wherein said leukocyte population is a mixed leukocyte population.

Claim 35

A process for producing and isolating granulocyto-angiotropin which comprises: a. culturing a leukocyte population; b. terminating the culturing; c. adding sufficient ammonium sulfate to the culture solution to achieve up to a 35% saturation; d. separating the precipitated proteins from the ammonium sulfate containing supernatant; e. redissolving and purifying said proteins by anion exchange chromagraphy, preparative molecular sieve filtration, cation exchange chromatography, hydroxyapatite chromatography, zone precipitation chromatography and recycling molecular sieve filtration; and f. isolating the granulocyto-angiotropin in highly purified form from the eluate of recycling molecular sieve filtration, after separating the accompanying foreign proteins.

Claim 36

A process for producing and isolating granulocyto-angiotropin which comprises: a. culturing a leukocyte population; b. terminating the culturing; c. adding sufficient ammonium sulfate to the culture solution to achieve up to a 35% saturation; d. separating the precipitated proteins from the ammonium sulfate containing supernatant; e. redissolving and purifying said proteins by anion exchange chromagraphy, preparative molecular sieve filtration, cation exchange chromatography, hydroxyapatite chromatography, zone precipitation chromatography and recycling molecular sieve filtration; and f. isolating the granulocyto-angiotropin in highly purified form from the eluate of recycling molecular sieve filtration, after separating the accompanying foreign proteins.

Claim 37

The process of claim 30, wherein said leukocyte population is a mixed leukocyte population.

Claim 38

The process of claim 30, wherein said leukocyte population consists of granulocytes.

Claim 39

The process of claim 30, further comprises inducing cell mitosis during culturing.

Claim 40

The process according to any one of claims 9 and 20 to 33, wherein the soluble portion of a leukocyte or inflamed tissue homogenate is used instead of the culture solution of the leukocytes.

Claim 41

Substantially pure monocytoangiotropin.

Claim 42

Substantially pure monocytoangiotropin.

Claim 43

Substantially pure granulocytoangiotropin.

Claim 44

Substantially pure granulocytoangiotropin.